Study Subject and Study Staff Personal Data Sample Clauses

Study Subject and Study Staff Personal Data. 6.2 Osobné údaje subjektov skúšania a personálu skúšania The Parties and Sponsor agree to adhere to the principles of medical confidentiality in relation to Study Subjects involved in the Study and to comply at all times with their respective obligations under all data protection applicable laws in relation to this Agreement and the protection of the Personal Data of Study Subjects and Study Staff, where the Sponsor, the Institution and the Investigator shall act as Data Controllers with regard to the processing and protection of this Personal Data each of them undertakes. Zmluvné strany a zadávateľ sa vo vzťahu k subjektom zapojeným do skúšania zaväzujú zachovávať zásady lekárskeho tajomstva a za všetkých okolností dodržiavať svoje príslušné povinnosti vyplývajúce zo všetkých právnych predpisov o ochrane osobných údajov v súvislosti s touto zmluvou a ochranou osobných údajov subjektov skúšania a personálu skúšania v prípadoch, kedy budú zadávateľ, zdravotnícke zariadenie a skúšajúci pôsobiť ako prevádzkovatelia osobných údajov, pokiaľ ide o spracovávanie a ochranu týchto osobných údajov, ku ktorej sa každý z nich zaväzuje. Both the Sponsor and the Parties shall maintain appropriate technical and organizational security measures to protect the Study Subjects’ and the Study Staff’s Personal Data they process in relation to this Agreement. Zadávateľ aj zmluvné strany budú udržiavať vhodné technické a organizačné bezpečnostné opatrenia na ochranu osobných údajov subjektov skúšania a personálu skúšania, ktoré budú spracovávať v súvislosti s touto zmluvou. Names of Study Staff may be processed in IQVIA’ study contacts database for study-related purposes only. Mená personálu skúšania sa môžu spracovávať v databáze kontaktov skúšania spoločnosti IQVIA len na účely súvisiace so skúšaním.
Sample 1
AutoNDA by SimpleDocs
Study Subject and Study Staff Personal Data. The Parties and Sponsor agree to adhere to the principles of medical confidentiality in relation to Study Subjects involved in the Study and to comply at all times with their respective obligations under all data protection applicable laws in relation to this Agreement and the protection of the Personal Data of Study Subjects and Study Staff, where the Sponsor, the Institution and the Investigator shall act as Data Controllers with regard to the processing and protection of this Personal Data each of them undertakes. 6.2 Osobní údaje Subjektu studie a studijního personálu Strany se zavazují zachovávat ve vztahu k Subjektům studie účastnícím se této Studie zásady lékařského tajemství a vždy dodržovat své závazky stanovené všemi příslušnými právními předpisy na ochranu osobních údajů, vztahujícími se na tuto Smlouvu, a zásadami ochrany Osobních údajů Subjektů studie a Studijního personálu v těch případech, kdy budou Zadavatel, Zdravotnické zařízení a Zkoušející jednat jako Správci údajů s ohledem na zpracování a ochranu Osobních údajů, které bude každý z nich zajišťovat. Both the Sponsor and the Parties shall maintain appropriate technical and organisational security measures to protect the Study Subjects’ and the Study Staff’s Personal Data they process in relation to this Agreement. Jak Zadavatel, tak smluvní Strany budou udržovat vhodná technická a organizační zabezpečovací opatření na ochranu Osobních údajů Subjektů studie a Studijního personálu, které budou v souvislosti s touto Smlouvou zpracovávat. Names of Study Staff may be processed in IQVIA’ study contacts database for study-related purposes only. Jména členů Studijního personálu mohou být v databázi kontaktů společnosti IQVIA pro studie zpracovány pouze pro účely související se Studií.
Sample 1
Study Subject and Study Staff Personal Data používány společností IQVIA, Zadavatelem a jejich pobočkami v souladu s Příslušnými právními předpisy, jak je uvedeno níže, a po přiměřenou dobu nezbytnou k níže uvedeným účelům. Osobní údaje Zkoušejícího mohou zahrnovat jména, kontaktní informace, pracovní zkušenosti a profesní kvalifikaci, přehled publikací, resumé, informace o absolvovaném vzdělání, a informace týkající se finančních vztahů nebo dalších potenciálních střetů zájmů a údaje o platbách uskutečněných vůči Příjemci plateb dle této Smlouvy, a to pro následující účely:
Sample 1

Related to Study Subject and Study Staff Personal Data

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Joint Network Implementation and Grooming Process Upon request of either Party, the Parties shall jointly develop an implementation and grooming process (the “Joint Grooming Process” or “Joint Process”) which may define and detail, inter alia:

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Access Toll Connecting Trunk Group Architecture 9.2.1 If CBB chooses to subtend a Verizon access Tandem, CBB’s NPA/NXX must be assigned by CBB to subtend the same Verizon access Tandem that a Verizon NPA/NXX serving the same Rate Center Area subtends as identified in the LERG.

  • Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Geological and Archeological Specimens If, during the execution of the Work, the Contractor, any Subcontractor, or any servant, employee, or agent of either should uncover any valuable material or materials, such as, but not limited to, treasure trove, geological specimens, archival material, archeological specimens, or ore, the Contractor acknowledges that title to the foregoing is vested in the Owner. The Contractor shall notify the Owner upon the discovery of any of the foregoing, shall take reasonable steps to safeguard it, and seek further instruction from the Design Professional. Any additional cost incurred by the Contractor shall be addressed under the provision for changed conditions. The Contractor agrees that the Geological and Water Resources Division and the Historic Preservation Division of the Georgia Department of Natural Resources may inspect the Work at reasonable times.

  • Study Area The study area focused on the Bulk Power System in South-Eastern New York between Albany and New York City, and voltages underlying systems at 115 kV and above in the lower Xxxxxx Valley (Zones G, H & I). In the PSS™E power flow base case provided by NYISO, facilities rated at 115 kV and above in PSS™E designated areas 6 through 11 are monitored in the study. These areas are: • Capital District • Xxxxxx • Millwood • Xxxxxxxxx • Con Ed • Long Island

  • COVID-19 Protocols Contractor will abide by all applicable COVID-19 protocols set forth in the District’s Reopening and COVID-19 Mitigation Plan and the safety guidelines for COVID-19 prevention established by the California Department of Public Health and the Ventura County Department of Public Health.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

Time is Money Join Law Insider Premium to draft better contracts faster.